TFII.TO -1.7C 0.13MU -51.63CRWD 5.64PANW 6.15SNOW -4.82V -0.14MAL.TO -0.14
Pfizer Inc (PFE)

NYSE:PFE

Pfizer Inc (PFE)

25.01
+0.10 (0.40%)
as of Jul 31, 2026, 8:00:00 pm Market Open.
581 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconAug 2, 2026, 12:00 am

This summary was created by AI, based on 23 opinions in the last 12 months.

Pfizer Inc. (PFE) is currently facing challenges following its pandemic-driven peak during which it surged due to COVID-19 vaccine sales. Experts have pointed out a lack of earnings momentum and concerns over a patent cliff, as key drugs have come off patent and the company needs to innovate to develop new blockbuster drugs. Despite these challenges, many analysts emphasize the attractive dividend yield, which remains around 6-8%. The company is pivoting towards growth areas such as obesity and oncology, and while there's a general belief that PFE is under pressure, patience from investors could yield positive results. Several insights indicate that while it may not attract immediate growth, the company’s efforts in acquisitions and drug development could eventually pay off, given time.

consensus icon
Consensus
Hold
valuation icon
Valuation
Undervalued
review icon
Similar
MRK
BUY

Pfizer Inc(PFE)

Dec 17, 2001
Excellent company. Good dividends.
Photo of Bob StodgellBob StodgellUnlock Rating
$40.33

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Dec 12, 2001
Great company, but economy is hitting all drug companies. Too high now.
Photo of Paul O'NeilPaul O'NeilUnlock Rating
$40.24

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Nov 28, 2001
(Was a top pick on Sept 26 up 16%) Still likes. A lot more upside yet.
Photo of Joe ConnollyJoe ConnollyUnlock Rating
$43.17

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Nov 28, 2001
Has a good pipeline for new drugs.
Photo of Mark Jackson, CFAMark Jackson, CFAUnlock Rating
$43.17

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
BUY ON WEAKNESS

Pfizer Inc(PFE)

Nov 08, 2001
Good products. Buy on weakness.
Photo of Brendan CaldwellBrendan CaldwellUnlock Rating
$42.30

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Oct 30, 2001
One of the best drug companies.
Photo of Neil MurdockNeil MurdockUnlock Rating
$42.45

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Oct 30, 2001
(Was a top pick on April 12 up 4.6%) Good sector.
Photo of Neil MurdockNeil MurdockUnlock Rating
$42.45

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Oct 25, 2001
Trades in a range. Good company.
Photo of Brendan CaldwellBrendan CaldwellUnlock Rating
$43.01

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Sep 27, 2001
Stable. Trading in the mid $20's is an earning multiple based on the 15% growth expected. Has competition.
Photo of Gordon Higgins, CA, MBAGordon Higgins, CA, MBAUnlock Rating
$39.75

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Sep 26, 2001
A defense stock. Ability to produce new drugs. Great patent protection. Great product line.
Photo of Joe ConnollyJoe ConnollyUnlock Rating
$38.55

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Sep 24, 2001
Likes. Best product line and a good pipeline. AT a good price.
Photo of Brendan CaldwellBrendan CaldwellUnlock Rating
$36.03

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Sep 24, 2001
Cheap. Great pipeline. Low risk.
Photo of Glenn Paradis, BA, CFAGlenn Paradis, BA, CFAUnlock Rating
$36.03

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Sep 21, 2001
Should do well even in a recession. Good price.
Photo of Steven WipperstegSteven WipperstegUnlock Rating
$35.80

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Sep 10, 2001
Prefers this and American Home over Lilly. Good product line.
Photo of Brad WillockBrad WillockUnlock Rating
$38.17

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Aug 30, 2001
Aging population. Nine new drugs coming out in the next 3 years. Great pipeline. 40% growth.
Photo of Joe ConnollyJoe ConnollyUnlock Rating
$38.30

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
Showing 841 to 855 of 885 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

EOG 3.18$148.69
SLB 0.68$49.59
SHEL 1.47$91.98
AAPL -24.52$308.91
AMZN 36.08$271.58
The ultimate 360° Tracker Your financial life in one place, automaticallywealthica-video

Today's Top Picks

TFII.TO -1.7$13.38
C 0.13$132.45
MU -51.63$823.03
CRWD 5.64$190.86
PANW 6.15$331.83

Popular Articles

Latest Sell Signals

AAPL -24.52$308.91
AAPL -24.52$308.91
AAPL -24.52$308.91
T.TO -1.7$13.38
CCA.TO -1.1$59.1

Most Recent Experts

Amy Raskin, CIO, Chevy Chase Trust

Amy Raskin, CIO, Chevy Chase Trust

Chevy Chase Trust

Stephanie Link, Chief investment strategist, Hightower

Stephanie Link, Chief investment strategist, Hightower

Hightower

Rob Sechan, Managing Partner, New Edge Capital

Rob Sechan, Managing Partner, New Edge Capital

New Edge Capital

Jim Lebenthal

Jim Lebenthal

Cerity Partners

Brianne Gardner

Brianne Gardner

Raymond James

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica

You may also like